CSPC will leverage its AI-powered drug discovery platform, which analyzes how target proteins bind with existing compounds to optimize and identify small molecules with the best potential for development.
Through this collaboration, M42 will incorporate SOPHiA GENETICS’ MSK-ACCESS® technology, powered by SOPHiA DDM™, into its testing services, enabling non-invasive genomic profiling of cancers using a simple blood sample.
This initiative also builds on the recommendations of the Abu Dhabi Public Health System Sustainability and Resilience (PHSSR) report, reinforcing the vision of a healthier Abu Dhabi.
Through this partnership, AstraZeneca and Revna Biosciences aim to transform cancer care in Ghana by not only enhancing diagnostic capabilities but also paving the way for targeted therapies tailored to individual patients’ genetic profiles.
The new R&D center will prioritize early-stage research and clinical development, enhanced by data science and an AI lab.